Cargando…

Epithelial mesenchymal transition status is associated with anti-cancer responses towards receptor tyrosine-kinase inhibition by dovitinib in human bladder cancer cells

BACKGROUND: Dovitinib (TKI-258) is a receptor tyrosine kinase (RTK) inhibitor targeting fibroblast growth factor receptor (FGFR) and further related RTKs. TKI-258 is under investigation as anticancer drug for the treatment of various cancers including bladder cancer with aberrant RTK signaling. Here...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hänze, Jörg, Henrici, Marcus, Hegele, Axel, Hofmann, Rainer, Olbert, Peter J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3866461/ https://www.ncbi.nlm.nih.gov/pubmed/24325461 http://dx.doi.org/10.1186/1471-2407-13-589

Ejemplares similares

Changes in prostaglandin E2 in patients with idiopathic overactive bladder syndrome after botulinum toxin type A treatment: is there a clinical benefit?
por: Hegele, Axel, et al.
Publicado: (2014)

Co-Regulation of Immune Checkpoint PD-L1 with Interferon-Gamma Signaling is Associated with a Survival Benefit in Renal Cell Cancer
por: Hänze, Jörg, et al.
Publicado: (2020)

Modulation of immune checkpoint regulators in interferon γ induced urothelial carcinoma and activated T-lymphocyte cells by cytostatics
por: Hänze, Jörg, et al.
Publicado: (2023)

Interaction Potential of the Multitargeted Receptor Tyrosine Kinase Inhibitor Dovitinib with Drug Transporters and Drug Metabolising Enzymes Assessed in Vitro
por: Weiss, Johanna, et al.
Publicado: (2014)

A Receptor Tyrosine Kinase Inhibitor, Dovitinib (TKI-258), Enhances BMP-2-Induced Osteoblast Differentiation In Vitro
por: Lee, Yura, et al.
Publicado: (2016)

Role of the ABL tyrosine kinases in the epithelial–mesenchymal transition and the metastatic cascade
por: Luttman, Jillian Hattaway, et al.
Publicado: (2021)

TOT Approach in stress urinary incontinence (SUI) – outcome in obese female
por: Frohme, Carsten, et al.
Publicado: (2014)

Dovitinib enhances temozolomide efficacy in glioblastoma cells
por: Thanasupawat, Thatchawan, et al.
Publicado: (2017)

Sex-related differences in urothelial cell carcinoma of the bladder in Germany
por: Scheller, Thomas, et al.
Publicado: (2018)

Dovitinib in patients with gastrointestinal stromal tumour refractory and/or intolerant to imatinib
por: Joensuu, Heikki, et al.
Publicado: (2017)

Epigenetic Mechanisms Influencing Epithelial to Mesenchymal Transition in Bladder Cancer
por: Monteiro-Reis, Sara, et al.
Publicado: (2019)

Neoadjuvant Dovitinib in Early- and Intermediate-Stage Hepatocellular Carcinoma
por: Rizzo, Alessandro, et al.
Publicado: (2022)

Cellular and soluble immune checkpoint signaling forms PD-L1 and PD-1 in renal tumor tissue and in blood
por: Keber, Corinna U., et al.
Publicado: (2022)

Tumor microenvironment and epithelial-mesenchymal transition in bladder cancer: Cytokines in the game?
por: Martins-Lima, Cláudia, et al.
Publicado: (2023)

Pilot study of dovitinib in patients with von Hippel-Lindau disease
por: Pilié, Patrick, et al.
Publicado: (2018)

Circulating microRNAs in patients with hormone receptor-positive, metastatic breast cancer treated with dovitinib
por: Shivapurkar, Narayan, et al.
Publicado: (2017)

Induction of Neuroendocrine Differentiation in Prostate Cancer Cells by Dovitinib (TKI-258) and its Therapeutic Implications
por: Yadav, Shalini S., et al.
Publicado: (2017)

Role of tyrosine kinases in bladder cancer progression: an overview
por: Zangouei, Amir Sadra, et al.
Publicado: (2020)

SAT-335 Resistin Induces Epithelial to Mesenchymal Transition (EMT) in Breast Cancer Cells through Activation of AXL Tyrosine Kinase Receptor
por: Weber, Daniel, et al.
Publicado: (2019)

Role of the Epithelial-Mesenchymal Transition in Bladder Cancer: From Prognosis to Therapeutic Target
por: Yun, Seok Joong, et al.
Publicado: (2013)

The roles and mechanism of IFIT5 in bladder cancer epithelial–mesenchymal transition and progression
por: Huang, Jun, et al.
Publicado: (2019)

Role of microRNA/Epithelial-to-Mesenchymal Transition Axis in the Metastasis of Bladder Cancer
por: Ashrafizadeh, Milad, et al.
Publicado: (2020)

Synergistic inhibition effect of TNIK inhibitor KY-05009 and receptor tyrosine kinase inhibitor dovitinib on IL-6-induced proliferation and Wnt signaling pathway in human multiple myeloma cells
por: Lee, Yura, et al.
Publicado: (2017)

The Epithelial-to-Mesenchymal Transition in Cancer
por: Roche, Joëlle
Publicado: (2018)

Epithelial–mesenchymal transition in cancer
por: Moustakas, Aristidis, et al.
Publicado: (2017)

Phase II Study of Dovitinib in Patients with Castration-Resistant Prostate Cancer (KCSG-GU11-05)
por: Choi, Yoon Ji, et al.
Publicado: (2018)

Reverse epithelial-mesenchymal transition contributes to the regain of drug sensitivity in tyrosine kinase inhibitor-resistant non-small cell lung cancer cells
por: Lee, An-Fu, et al.
Publicado: (2017)

Employing an orthotopic model to study the role of epithelial-mesenchymal transition in bladder cancer metastasis
por: Roth, Beat, et al.
Publicado: (2016)

Shikonin suppresses the epithelial-to-mesenchymal transition by downregulating NHE1 in bladder cancer cells
por: Mo, Lijun, et al.
Publicado: (2021)

YKL-40 promotes invasion and metastasis of bladder cancer by regulating epithelial mesenchymal transition
por: Hao, Hailong, et al.
Publicado: (2021)

Mixed lineage kinase ZAK promotes epithelial–mesenchymal transition in cancer progression
por: Li, Linna, et al.
Publicado: (2018)

Dovitinib induces mitotic defects and activates the G(2) DNA damage checkpoint
por: Man, Wing Yu, et al.
Publicado: (2014)

Dovitinib preferentially targets endothelial cells rather than cancer cells for the inhibition of hepatocellular carcinoma growth and metastasis
por: Chen, Zhi-Yuan, et al.
Publicado: (2012)

Epithelial to mesenchymal transition and breast cancer
por: Tomaskovic-Crook, Eva, et al.
Publicado: (2009)

Epithelial-Mesenchymal Transition and Breast Cancer
por: Wu, Yanyuan, et al.
Publicado: (2016)

Mesenchymal-Epithelial Transition in Oral Cancer
por: Patil, Shankargouda, et al.
Publicado: (2015)

Steroid sulfatase promotes invasion through epithelial-mesenchymal transition and predicts the progression of bladder cancer
por: Shimizu, Yasuomi, et al.
Publicado: (2018)

Glucose promotes epithelial‐mesenchymal transitions in bladder cancer by regulating the functions of YAP1 and TAZ
por: Li, Shi, et al.
Publicado: (2020)

Flavanomarein inhibits high glucose-stimulated epithelial-mesenchymal transition in HK-2 cells via targeting spleen tyrosine kinase
por: Zhang, Nan-nan, et al.
Publicado: (2020)

Dihydropyrimidinase Like 2 Promotes Bladder Cancer Progression via Pyruvate Kinase M2-Induced Aerobic Glycolysis and Epithelial–Mesenchymal Transition
por: Zou, Jun, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_8q66af8n3jdnirfa0ogp5bf3vg